Intellia Stock Plunges 22.77% on Safety Concerns

On May 29, 2025, Intellia's stock experienced a significant drop of 22.77% in pre-market trading.

Intellia Therapeutics' stock plummeted following a safety update from its ongoing Phase 3 MAGNITUDE study. The update revealed that a patient in a late-stage trial for a heart disease drug recently experienced a severe adverse event, raising concerns about the safety of the gene editing therapy nex-z, which is being developed in partnership with Regeneron for ATTR-CM.

This safety concern has rekindled investor worries about the long-term safety and risk/reward profile of gene editing therapies. Analysts, including those from JPMorgan, have expressed that this update could further dampen investor confidence in the company's prospects.